All In Biotech

Drug Trial Radar · NCT05767866

Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR

Safety and Preliminary Efficacy of YK-029A, a Novel EGFR TKI, in Patients With Advanced NSCLC Harboring ex20ins, T790M or Rare Mutations

Last checked: Nov 19, 2026Latest source record: Mar 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

160

Planned (sponsor's estimate)

Start

Mar 30, 2018

Primary completion

Dec 30, 2023

Study completion May 30, 2024

Sponsor

Sponsor type
Industry
First posted
Mar 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aimed to evaluate the safety and preliminary efficacy of YK-029A, a novel third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in treated or untreated patients with advanced non-small cell lung cancer (NSCLC).

Conditions

  • Treatment
  • Treatment Side Effects

Interventions

  • YK-029ADrug

    Daily dose of YK-029A

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants that Experience Adverse Events (AEs) and Serious Adverse Events (SAEs) .Time frame: Cycle 1 (Cycle length is equal to [=] 28 days)
  2. Part 1: Number of Participants with Clinically Significant Abnormal Laboratory Values.Time frame: Cycle 1 (Cycle length is equal to [=] 28 days)
  3. Part 1: Number of Participants with First Cycle Dose-Limiting Toxicities (DLTs).Time frame: Cycle 1 (Cycle length is equal to [=] 28 days)
  4. Part 1: DLTs of Orally Administered YK-029A.Time frame: Cycle 1 (Cycle length is equal to [=] 28 days)
  5. Part 1: Number of Participants with First Cycle Dose-Limiting Toxicities (DLTs).Time frame: Cycle 1 (Cycle length is equal to [=] 28 days)
  6. Part 1: Maximum Tolerated Dose (MTD) of Orally Administered YK-029ATime frame: Cycle 1 (Cycle length is equal to [=] 28 days)
  7. Part 2: Objective Response Rate (ORR) according to RECIST 1.1 by IRCTime frame: Up to 36 months after first dose
  8. Part 3: Objective Response Rate (ORR) according to RECIST 1.1 by IRCTime frame: Up to 36 months after first dose

Locations

35 sites in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, China · Recruiting

  • Beijing Chest Hospital Affiliated to Capital Medical University

    Beijing, China · Recruiting

  • Beijing Hospital

    Beijing, China · Recruiting

  • Beijing Tiantan Hospital affiliated to Capital Medical University

    Beijing, China · Recruiting

  • National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

    Beijing, China · Recruiting

  • Peking University Cancer Hospital

    Beijing, China · Recruiting

  • The Fifth Medical Center of the Chinese People's Liberation Army General Hospital

    Beijing, China · Recruiting

  • Anhui Provincial Cancer Hospital

    Hefei, Anhui, China · Recruiting

  • Anhui Provincial Hospital

    Hefei, Anhui, China · Recruiting

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China · Recruiting

  • People's Hospital of Guangxi Zhuang Autonomous Region

    Nanjing, Guangxi, China · Recruiting

  • Affiliated Tumor Hospital of Guangxi Medical University

    Nanning, Guangxi, China · Recruiting

  • Affiliated Cancer Hospital of Harbin Medical University

    Harbin, Heilongjiang, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhenzhou, Henan, China · Recruiting

  • Renmin Hospital of Wuhan University

    Wuhan, Hubei, China · Recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

  • Xiangya Hospital Central South University

    Changsha, Hunan, China · Recruiting

  • Nanjing Drum Tower Hospital Affiliated to Medical School of Nanjing University

    Nanjin, Jiangsu, China · Recruiting

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China · Recruiting

  • Nanjing Chest Hospital

    Nanjing, Jiangsu, China · Recruiting

  • Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China · Recruiting

  • Xuzhou Central Hospital

    Xuzhou, Jiangsu, China · Recruiting

  • First Hospital of Jilin University

    Changchun, Jilin, China · Recruiting

  • Jilin Tumor Hospital

    Changchun, Jilin, China · Recruiting

  • Liaoning Cancer Hospital and Institute

    Shenyang, Liaoning, China · Recruiting

  • Shengjing Hospital Affiliated to China Medical University

    Shenyang, Liaoning, China · Recruiting

  • The First Affiliated Hospital of China Medical University

    Shenyang, Liaoning, China · Recruiting

  • Shanxi Cancer Hospital

    Taiyuan, Shanxi, China · Recruiting

  • the First Affiliated Hospital; Medical College of Xi'an Jiaotong University

    Xi’an, Shanxi, China · Recruiting

  • Tianjin Cancer Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • Cancer in Zhejiang Province

    Hangzhou, Zhejiang, China · Recruiting

  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.